India, the 'pharmacy of the world' banks on bilateral talks for relief from planned US tariffs

Indian drugmakers are seeking bilateral discussions with the U.S. to avoid President Donald Trump’s proposed 25% tariff on pharmaceutical imports, according to the Indian Pharmaceutical Alliance (IPA). The U.S. is India's largest market, accounting for $8.7 billion (31%) of total pharma exports in fiscal 2024.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/9FwTLAX
via IFTTT

Read More

India becoming an attractive option for global pharmaceutical supply chain: Macquarie Report

India's CRDMO industry is projected to grow from USD 7 billion to USD 14 billion by 2028, driven by pharmaceutical outsourcing and regulatory support. The industry's growth could reach a high-teens CAGR due to factors like the US Biosecure Act, potentially pushing it to USD 22 billion by 2030.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/J4TldtY
via IFTTT

Read More

Not scared of Trump's threats? India's drug, auto exporters see limited impact of US tariffs

Indian exporters believe that US President Trump's proposed tariffs on automobile and pharmaceutical imports will not significantly affect their competitiveness. Industry leaders suggest adjusting domestic policies to mitigate any potential impact. Indian pharmaceuticals and auto components are expected to remain resilient despite the potential for increased tariffs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/q7BYo04
via IFTTT

Read More

Generic pain, margin loss: Drug companies may find it hard to adjust with Trump's tariff plans

US President Trump's 25% tariff plan on pharmaceuticals jeopardizes Indian pharma exports, making generics pricier and impacting margins. Indian companies and stock markets brace for the impact, as India dominates with 30% of exports to the US. Firms may face challenges balancing costs and profit margins.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/SfajAUJ
via IFTTT

Read More

Tata Group to invest Rs 500 crore in Breach Candy Hospital Expansion

Tata Group will invest Rs 500 crore in Breach Candy Hospital, becoming its largest financial backer. This will allow Tata Group to add three representatives to the board and support infrastructure and technology improvements. Chairman N Chandrasekaran will replace Deepak Parekh as chairman of Breach Candy Hospital Trust from October 2025, while Parekh will remain a trustee.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/lxONraf
via IFTTT

Read More

Pharma market in good health; lifestyle diseases may be rising

The other leading molecules in the same segment, like rosuvastatin and telmisartan, continued to grow in line with the therapy segment, the data showed. According to Pharmarack, emerging molecules like vericiguat, finerenone and midodrine also posted robust growth.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/vsrhiJD
via IFTTT

Read More

Practo ​a​ppoints Jagnoor Singh as ​C​OO

Practo has appointed Jagnoor Singh as its new COO to boost growth and refine processes. With 16 years of experience at top firms, Singh will collaborate with CEO Shashank ND to expand into new markets and enhance existing ones, aiming to make healthcare more accessible and affordable.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/9PF1sY0
via IFTTT

Read More